

Racemic peptides from Amyloid beta and Amylin form rippled β -sheets rather than pleated β -sheets.

Amaruka Hazari,^{†,a,} Michael R. Sawaya,^{‡,a} Maria Sajimon,[†] Niko Vlahakis,[‡] Jose Rodriguez,[‡] David Eisenberg,[‡] Jevgenij A. Raskatov^{†,*}*

[†] Dept. of Chemistry and Biochemistry, UCSC, 1156 High Street, Santa Cruz, CA 95064, USA.

[‡] Dept. of Chemistry and Biochemistry, UCLA, 607 Charles E. Young Drive East Box 951569, Los Angeles, CA 90095-1569, USA.

[a] Denotes equal contribution.

[*] Corresponding author emails: jraskato@ucsc.edu; amhazari@ucsc.edu

SUPPORTING INFORMATION

Material and Methods

Peptide Synthesis and Crystallization

Peptides were purchased from Anaspec or synthesized on pre-loaded Wang resins by standard Fmoc based, solid-phase peptide chemistry. Syntheses were performed manually at 0.2 mM scale relative to resin loading. The peptides were cleaved and deprotected with a mixture consisting of trifluoroacetic acid (10 mL), tri-isopropylsilane (1 mL), and liquefied phenol (0.5 mL). The cleavage solution was added to the resins and agitated for 2 h. The solution was then evaporated to 2 mL under nitrogen gas, and the peptides precipitated with cold diethyl ether and centrifuged at 6000 rpm. The peptide pellet was washed with cold diethyl ether, dried, dissolved in 1:1 acetonitrile:water, flash frozen in liquid nitrogen, and lyophilized. No further purification was performed prior to crystallization.

MVGGVV:mvgvv HFIP

Stock solutions of the L-MVGGVV and D-mvgvv peptides in Nanopure water were prepared separately at concentrations of 2 mg/mL. Aliquots (100 uL) of each solution were combined and hexafluoroisopropanol (20 uL) was subsequently added. Colorless needles grew over the course of several days.

MVGGVV:mvgvv PFPa

Stock solutions of the L-MVGGVV and D-mvgvv peptides in Nanopure water were prepared separately at concentrations of 2 mg/mL. Aliquots (100 uL) of each solution were combined and pentafluoropropionic acid (20 uL) was subsequently added. Colorless needles grew over the course of several days.

KLVFFA:klvffa

Stock solutions of the L-KLVFFA and D-klvffa peptides in Nanopure water were prepared separately at concentrations of 2 mg/mL. Aliquots (100 uL) of each solution were combined and hexafluoroisopropanol (20 uL) was subsequently added. Colorless needles grew over the course of several weeks.

Ac-KLVFFAE-NH₂:Ac-klvffae-NH₂

Solutions of the L-Ac-KLVFFAE-NH₂ and D-Ac-klvffae-NH₂ peptides in Nanopure water were prepared separately at concentrations of 1 mg/mL. The solutions were combined and hexafluoroisopropanol (100 uL) was then added. A gel formed immediately. Over a period of several weeks, the gel separated and subsequently formed colorless needles.

AILSS:ailss

Stock solutions of the L-AILSS and d-ailss peptides in Nanopure water were prepared separately at concentrations of 40 mg/mL. Aliquots (200 uL) of each solution were combined and hexafluoroisopropanol (47 uL) was subsequently added. Colorless needles grew over the course of several hours.

Crystallographic Structure Determination.

Microfocus X-ray beam optics were required to measure crystal diffraction intensities from our crystals since they were needle-shaped, and less than 5 microns thick. We used microfocus beamline 24-ID-E of the Advanced Photon Source located at Argonne National Laboratory. Crystals were cooled to a

temperature of 100 K. Diffraction data were indexed, integrated, scaled, and merged using the programs XDS and XSCALE.¹ Data collection statistics are reported in Supplemental Table 1. Initial phases for KLVFFAE:klvffae were obtained by molecular replacement with the program Phaser² using PDB entry 3ow9 as the search model. Phases for the four remaining sets of diffraction intensities were obtained by direct methods using the program ShelxD³ (for MVGGVV:mvggvv) and ShelxT⁴ (for KLVFFA:klvffa and AILSS:ailss structures). Model building was performed using the graphics program Coot⁵. Atomic refinement was performed using the program Phenix.⁶ Subsequent rounds of refinement were performed using the program Refmac⁷ in all cases except MVGGVV:mvggvv with PFPA. Structure illustrations were created using PyMOL.⁸

Table S1. Data Collection and Refinements Statistics from Crystals of Amyloid Segments.

Data collection and refinement statistics from crystals of Amyloid segments

| Peptide, racemic mixture | ¹⁶ KLVFFA ²¹ Amyloid β TFA | ¹⁶ KLVFFAE ²² Amyloid β | ³⁵ MVGGVV ⁴⁰ Amyloid β HFIP | ³⁵ MVGGVV ⁴⁰ Amyloid β PFPA | ²⁵ AILSS ²⁹ IAPP |
|--|--|--|---|---|---|
| Data Collection | | | | | |
| Beamline | APS 24-ID-E | APS 24-ID-E | APS 24-ID-E | APS 24-ID-E | APS 24-ID-E |
| Space group | P-1 | P2 ₁ /c | P-1 | P2 ₁ /c | P-1 |
| Resolution (Å) | 1.50 (1.56-1.50)* | 2.00 (2.15-2.00) | 1.10 (1.16-1.10) | 1.10 (1.16-1.10) | 1.10 (1.16-1.10) |
| Unit cell dimensions: a,b,c (Å) | 11.69, 11.70, 18.51 | 24.92, 11.53, 21.54 | 9.42, 11.22, 21.12 | 9.56, 18.57, 20.83 | 9.50, 9.88, 16.29 |
| Unit cell angles: α,β,γ (°) | 89.96, 91.78, 110.51 | 90.0, 97.73, 90.0 | 96.57, 89.57, 94.95 | 90.0, 98.4, 90.0 | 90.45, 98.13, 94.38 |
| Measured reflections | 8550 (867) | 1891 (234) | 22565 (1253) | 16074 (869) | 9671 (428) |
| Unique reflections | 1424 (139) | 785 (113) | 2980 (224) | 2485 (155) | 1898 (101) |
| Overall completeness (%) | 97.0 (95.2) | 87.3 (72.0) | 85.8 (43.2) | 82.5 (35.9) | 80.3 (30.6) |
| Overall redundancy | 6.0 (6.2) | 2.4 (2.1) | 7.6 (5.6) | 6.5 (5.6) | 5.1 (4.2) |
| Overall R _{merge} | 0.157 (1.16) | 0.140 (0.742) | 0.174 (1.897) | 0.099 (0.234) | 0.142 (0.955) |
| CC _{1/2} | 99.7 (76.7) | 99.4 (76.7) | 99.5 (62.7) | 99.1 (97.7) | 99.2 (65.1) |
| Overall I/δ | 4.5 (1.4) | 2.9 (1.1) | 4.9 (0.8) | 10.3 (5.3) | 4.9 (1.4) |
| Refinement | | | | | |
| R _{work} / R _{free} | 0.225 / 0.227 | 0.465 / 0.490 | 0.189 / 0.204 | 0.152 / 0.177 | 0.152/0.179 |
| RMSD bond length (Å) | 0.012 | 0.015 | 0.018 | 0.007 | 0.005 |
| RMSD angle (°) | 1.6 | 1.8 | 1.9 | 1.4 | 0.8 |
| Number of peptide atoms** | 52 | 64 | 43 | 38 | 34 |
| Number of water atoms | 3 | 0 | 2 | 1 | 5 |
| Number of other solvent atoms | 7 | 0 | 36 | 10 | 0 |
| Average B-factor of peptide (Å ²) | 22.8 | 37.3 | 20.5 | 5.8 | 11.8 |
| Average B-factor of water (Å ²) | 29.7 | N/A | 26.4 | 5.5 | 20.0 |
| Average B-factor other solvent (Å ²) | 41.3 | N/A | 26.4 | 9.8 | N/A |
| PDB ID code | 8T89 | N/A | 8T84 | 8T82 | 8T86 |

*Numbers in parentheses report statistics in highest resolution shell.

**Count excludes hydrogen atoms.

Table S2. Torsional angles of the various rippled and pleated MVGGVV X-ray structures

Rippled MVGGVV:mvggvv HFIP | [8T84.pdb](#)

| residue | Phi | psi | mirror image phi | mirror image psi |
|---------|---------|--------|------------------|------------------|
| M35 | - | 135.49 | - | -140.35 |
| V36 | -116.45 | 115.49 | 116.45 | -115.49 |
| G37 | -69.04 | 151.79 | 69.04 | -151.79 |
| G38 | -74.76 | 168.62 | 74.76 | -169.62 |
| V39 | -129.56 | 136.71 | 129.56 | -136.71 |
| V40 | -112.93 | - | 112.93 | - |

Rippled | MVGGVV:mvggvv | PFPA | [8T82.pdb](#)

| residue | Phi | psi | mirror image phi | mirror image psi |
|---------|---------|--------|------------------|------------------|
| M35 | - | 146.95 | | |
| V36 | -110.01 | 111.67 | 110.01 | 110.01 |
| G37 | -68.15 | 153.07 | 68.15 | 68.15 |
| G38 | -68.76 | 168.97 | 68.17 | 68.17 |
| V39 | -133.94 | 124.52 | 133.94 | 133.94 |
| V40 | -107.35 | - | 107.35 | - |

Pleated | L-MVGGVV | [2ona.pdb](#)

| residue | phi sheet 1 | psi sheet 1 | phi sheet 2 | psi sheet 2 |
|---------|-------------|-------------|-------------|-------------|
| M35 | - | 132.62 | - | 140.82 |
| V36 | -137.37 | 140.44 | -136.85 | 134.61 |
| G37 | -165.44 | 155.39 | -148.83 | 151.62 |
| G38 | -146.02 | 145.39 | -158.83 | 159.17 |
| V39 | -134.25 | 123.76 | -141.54 | 137.17 |

| | | | | |
|-----|---------|---|---------|---|
| V40 | -109.36 | - | -144.16 | - |
|-----|---------|---|---------|---|

Pleated | L-MVGGVV | 2okz.pdb

| residue | phi sheet 1 | psi sheet 1 | phi sheet 2 | psi sheet 2 |
|---------|-------------|-------------|-------------|-------------|
| M35 | - | 156.79 | - | 138.86 |
| V36 | -145.95 | 133.30 | -128.52 | 119.38 |
| G37 | -133.02 | 147.55 | -138.60 | 146.96 |
| G38 | -140.74 | 139.48 | -134.19 | 126.70 |
| V39 | -131.19 | 131.12 | -113.89 | 116.80 |
| V40 | -128.20 | - | -135.39 | - |

Table S3. Sheet-Sheet Interface Properties.

Table of Sheet-Sheet interface Properties

| Chirality | Peptide Crystal | Area Buried (Å ²) | Shape Complementarity | Sheet structure | Strand orientation | Strand registration | Sheet-to-sheet orientation | Dry or solvated? | PDB ID |
|---|----------------------------------|-------------------------------|-----------------------|-----------------|--------------------|---------------------|----------------------------|------------------|--------|
| Crystal structures containing MVGGVV sequence | | | | | | | | | |
| L+D | MVGGVV in HFPA | 63 | 0.75 | Rippled | Antiparallel | In-register | Face-to-face | Solvated | 8t84 |
| L+D | MVGGVV in PFPA | 78 | 0.75 | Rippled | Antiparallel | In-register | Face-to-edge | Solvated | 8t82 |
| L | MVGGVV-form 1 | 92 | 0.76 | Pleated | Antiparallel | In-register | Face-to-face | Dry | 2ona |
| L | MVGGVV-form 2 | 103 | 0.82 | Pleated | Antiparallel | In-register | Face-to-face | Dry | 2okz |
| Crystal structures containing KLVFFA sequence | | | | | | | | | |
| L+D | KLVFFAE | 137 | 0.49 | Rippled | Antiparallel | Out-of-register | Face-to-face | Dry | N/A |
| L+D | KLVFFA | 96 | 0.85 | Rippled | Antiparallel | Out-of-register | Face-to-face | Dry | 8t89 |
| L | KLVFFA-form1 | 113 | 0.58 | Pleated | Antiparallel | In-register | Face-to-face | Dry | 2y2a |
| L | KLVFFA-form2 | 131 | 0.54 | Pleated | Antiparallel | In-register | Face-to-face | Dry | 3ow9 |
| L | KLVFFA-form3 | 114 | 0.55 | Pleated | Antiparallel | In-register | Face-to-face | Dry | 2y29 |
| Crystal structures containing AILSS sequence | | | | | | | | | |
| L+D | AILSS | 104 | 0.85 | Rippled | Antiparallel | In-register | Face-to-face | Dry | 8t86 |
| L | AILSST | 112 | 0.57 | Pleated | Antiparallel | In-register | Face-to-face | Dry | 3fod |
| Classical steric zipper structures, select examples | | | | | | | | | |
| L | GNQQQNY from Sup35 | 143 | 0.86 | Pleated | Parallel | In-register | Face-to-face | Dry | 1yjo |
| L | LVEALYL from Insulin | 205 | 0.81 | Pleated | Parallel | In-register | Face-to-face | Dry | 3hyd |
| L | VVTGTVA from α -Synuclein | 162 | 0.94 | Pleated | Parallel | In-register | Face-to-face | Dry | 4r0w |
| L | VQIVYK from Tau | 114 | 0.72 | Pleated | Parallel | In-register | Face-to-face | Dry | 2on9 |
| L | VQIINK from Tau | 146 | 0.85 | Pleated | Parallel | In-register | Face-to-face | Dry | 6odg |
| L | NFGAILS from IAPP | 180 | 0.81 | Pleated | Antiparallel | Out-of-register | Face-to-face | Dry | 5e5v |

References

- (1) Kabsch, W. XDS. *Acta Crystallogr D Biol Crystallog* **2010**, *66* (Pt 2), 125-132. DOI: 10.1107/s0907444909047337.
- (2) McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software. *J Appl Crystallogr* **2007**, *40* (Pt 4), 658-674. DOI: 10.1107/s0021889807021206.
- (3) Sheldrick, G. M. A short history of SHELX. *Acta Crystallogr A* **2008**, *64* (Pt 1), 112-122. DOI: 10.1107/s0108767307043930.
- (4) Sheldrick, G. M. SHELXT - integrated space-group and crystal-structure determination. *Acta Crystallogr A Found Adv* **2015**, *71* (Pt 1), 3-8. DOI: 10.1107/s2053273314026370 From NLM.
- (5) Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot. *Acta Crystallogr D Biol Crystallog* **2010**, *66* (Pt 4), 486-501. DOI: 10.1107/s0907444910007493.
- (6) Liebschner, D.; Afonine, P. V.; Baker, M. L.; Bunkóczki, G.; Chen, V. B.; Croll, T. I.; Hintze, B.; Hung, L. W.; Jain, S.; McCoy, A. J.; et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. *Acta Crystallogr D Struct Biol* **2019**, *75* (Pt 10), 861-877. DOI: 10.1107/s2059798319011471.
- (7) Murshudov, G. N.; Skubák, P.; Lebedev, A. A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. D.; Long, F.; Vagin, A. A. REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallogr D Biol Crystallog* **2011**, *67* (Pt 4), 355-367. DOI: 10.1107/s0907444911001314.
- (8) *The PyMOL Molecular Graphics System*; Schrödinger, LLC: Version 1.2r3pre. (accessed).